单抗制剂工艺员
百奥泰生物科技(广州)有限公司
- 公司规模:150-500人
- 公司性质:合资(欧美)
- 公司行业:制药/生物工程
职位信息
- 发布日期:2017-01-26
- 工作地点:广州
- 招聘人数:若干人
- 工作经验:3-4年经验
- 学历要求:大专
- 职位月薪:1-10000000/年
- 职位类别:生物工程/生物制药
职位描述
职位描述:
工作职责:
1、协助生产部经理按要求组织生产,保证生产人员严格按生产工艺规程和岗位操作法进行生产。
2、按工艺规程、岗位操作法、生产设备操作SOP的相关规定,检查各工序生产工人生产操作情况。
3、对生产现场出现的质量、技术问题要及时妥善处理。
4、按工艺要求及时填写生产指令、包装指令,并经相关部门审核批准后下发到各岗位。
5、负责生产工艺规程的发放、收集以及批生产记录、批包装记录的收集整理、归档保管。
6、负责生产部各班组清场后的复核,并对清场质量严格把关负责。
7、接受公司领导及生产部经理临时交给的任务。
入职要求:
1、药学及相关专业大专或以上学历,三年以上制药企业相关工作经验;
2、有药品设备操作及现场管理经验,懂单抗制剂或无菌制剂的生产工艺流程;
3、熟悉药品GMP知识,有新版GMP认证经验优先考虑;
4、熟悉洁净生产车间的日常管理工作,良好的协调、沟通、管理能力,执行力较强。
举报
分享
工作职责:
1、协助生产部经理按要求组织生产,保证生产人员严格按生产工艺规程和岗位操作法进行生产。
2、按工艺规程、岗位操作法、生产设备操作SOP的相关规定,检查各工序生产工人生产操作情况。
3、对生产现场出现的质量、技术问题要及时妥善处理。
4、按工艺要求及时填写生产指令、包装指令,并经相关部门审核批准后下发到各岗位。
5、负责生产工艺规程的发放、收集以及批生产记录、批包装记录的收集整理、归档保管。
6、负责生产部各班组清场后的复核,并对清场质量严格把关负责。
7、接受公司领导及生产部经理临时交给的任务。
入职要求:
1、药学及相关专业大专或以上学历,三年以上制药企业相关工作经验;
2、有药品设备操作及现场管理经验,懂单抗制剂或无菌制剂的生产工艺流程;
3、熟悉药品GMP知识,有新版GMP认证经验优先考虑;
4、熟悉洁净生产车间的日常管理工作,良好的协调、沟通、管理能力,执行力较强。
职能类别: 生物工程/生物制药
公司介绍
百奥泰生物制药股份有限公司(Bio-Thera Solutions, Ltd.)是一家由海外留学归国精英创办的生物制药企业,致力于新一代抗体创新药和生物类似药的研发,用于治疗癌症、自身免疫性疾病、心血管疾病以及其它危及人类生命的重大疾病。
作为新一代抗体药物研发引领者,百奥泰成功搭建了领先的抗体药物技术平台,并建立起丰富的创新药物和生物类似药物产品管线。 在研产品25个,其中8个候选产品处于不同临床阶段。治疗自身免疫疾病的阿达木单抗类似药(原研药为全球“药王”)有望在同类产品中成为中国首仿;治疗心血管疾病的巴替非班是我国第一个针对β3整合素受体的国家1.1类新药。治疗乳腺癌的抗HER2 ADC注射液、治疗多种实体瘤的贝伐珠单抗类似药、治疗自身免疫疾病的托珠单抗类似药已进入Ⅲ期临床。
百奥泰广纳贤才,组建了一支具有丰富生物药物研发和产业化经验的优秀人才队伍。现有员工400余人,硕博士比例高达60%,其中不乏多位资深海外学成归国专家、“千人计划”专家、广东省首批“科技领军人才”、广东省“珠江人才计划”创新创业团队、广州市“百人计划”等优秀成员。
“科学驱动创新,创新只为生命”,百奥泰始终以病人的福祉作为企业的首要核心价值,通过创新研发为病人提供安全、有效、可负担的优质产品,以满足亟待解决的治疗需求。坚持创新,追求卓越,百奥泰部分产品和技术力争成为中国乃至全球的引领者!
Bio-Thera Solutions Ltd, a leading biotechnology company in China, is dedicated to researching and developing innovative and biosimilar therapeutics for the treatment of cancers, autoimmune, cardiovascular diseases, and other serious medical conditions.
Bio-Thera is a leader in next generation antibody discovery and engineering. The company has developed a suite of proprietary technologies for target discovery, antibody engineering and therapeutic development, and antibody manufacturing capability. We have more than 25 research projects, 8 of which are in the clinical stage. BAT1406 was the first adalimumab (global top 1 best-selling drug) biosimilar submitted to CFDA for IND application, and is approaching marketing application submission. BAT2094 is the first class 1.1 new drug targeting β3 integrin in China. Other three programs in late clinical stage are bevacizumab biosimilar for cancer treatment, tocilizumab biosimilar for autoimmune diseases, and BAT8001, an antibody-drug conjugate, targeting HER2 positive cancers.
Bio-Thera built an excellent talent team with biological medicine experience of research and industrialization. The company has nearly 400 staff, the ratio of Master and Dr is as high as 60%, including a number of senior overseas returnee experts, "Thousand Talents Plan" experts, leading talents of Guangdong "Pearl River Talents Plan" innovative entrepreneurial team, "Hundred Talents Plan" experts in Guangzhou and many outstanding members .
"Driven By Science, innovation for life", Bio-Thera has always been to the health of patients as the first core value of enterprise, through innovative research and development for the patient to provide a safe, effective and affordable products, to meet the treatment needs . Persist in innovation and pursue excellence, Bio-Thera’s products and technologies strive to become the leader of China and even the world!
作为新一代抗体药物研发引领者,百奥泰成功搭建了领先的抗体药物技术平台,并建立起丰富的创新药物和生物类似药物产品管线。 在研产品25个,其中8个候选产品处于不同临床阶段。治疗自身免疫疾病的阿达木单抗类似药(原研药为全球“药王”)有望在同类产品中成为中国首仿;治疗心血管疾病的巴替非班是我国第一个针对β3整合素受体的国家1.1类新药。治疗乳腺癌的抗HER2 ADC注射液、治疗多种实体瘤的贝伐珠单抗类似药、治疗自身免疫疾病的托珠单抗类似药已进入Ⅲ期临床。
百奥泰广纳贤才,组建了一支具有丰富生物药物研发和产业化经验的优秀人才队伍。现有员工400余人,硕博士比例高达60%,其中不乏多位资深海外学成归国专家、“千人计划”专家、广东省首批“科技领军人才”、广东省“珠江人才计划”创新创业团队、广州市“百人计划”等优秀成员。
“科学驱动创新,创新只为生命”,百奥泰始终以病人的福祉作为企业的首要核心价值,通过创新研发为病人提供安全、有效、可负担的优质产品,以满足亟待解决的治疗需求。坚持创新,追求卓越,百奥泰部分产品和技术力争成为中国乃至全球的引领者!
Bio-Thera Solutions Ltd, a leading biotechnology company in China, is dedicated to researching and developing innovative and biosimilar therapeutics for the treatment of cancers, autoimmune, cardiovascular diseases, and other serious medical conditions.
Bio-Thera is a leader in next generation antibody discovery and engineering. The company has developed a suite of proprietary technologies for target discovery, antibody engineering and therapeutic development, and antibody manufacturing capability. We have more than 25 research projects, 8 of which are in the clinical stage. BAT1406 was the first adalimumab (global top 1 best-selling drug) biosimilar submitted to CFDA for IND application, and is approaching marketing application submission. BAT2094 is the first class 1.1 new drug targeting β3 integrin in China. Other three programs in late clinical stage are bevacizumab biosimilar for cancer treatment, tocilizumab biosimilar for autoimmune diseases, and BAT8001, an antibody-drug conjugate, targeting HER2 positive cancers.
Bio-Thera built an excellent talent team with biological medicine experience of research and industrialization. The company has nearly 400 staff, the ratio of Master and Dr is as high as 60%, including a number of senior overseas returnee experts, "Thousand Talents Plan" experts, leading talents of Guangdong "Pearl River Talents Plan" innovative entrepreneurial team, "Hundred Talents Plan" experts in Guangzhou and many outstanding members .
"Driven By Science, innovation for life", Bio-Thera has always been to the health of patients as the first core value of enterprise, through innovative research and development for the patient to provide a safe, effective and affordable products, to meet the treatment needs . Persist in innovation and pursue excellence, Bio-Thera’s products and technologies strive to become the leader of China and even the world!
联系方式
- Email:bd@bio-thera.com
- 公司地址:地址:span黄埔区开源大道11号科技企业加速器A6幢5楼